We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Unexplained Liver Disease Diagnosed by Whole-Exome Sequencing

By LabMedica International staff writers
Posted on 29 Apr 2019
Print article
Image: The use of WES on adults with liver disease of unknown cause illustrates the potential clinical value of genome rounds in the individual assessment and medical care of patients (Photo courtesy of the Yale School of Medicine / Journal of Hepatology).
Image: The use of WES on adults with liver disease of unknown cause illustrates the potential clinical value of genome rounds in the individual assessment and medical care of patients (Photo courtesy of the Yale School of Medicine / Journal of Hepatology).
A recent paper promoted the use of whole-exome sequencing (WES) to detect and diagnose cases of unexplained liver disease.

Chronic liver disease is a significant health problem affecting more than four million people and leading to over 40,000 deaths annually in the United States alone. It often remains undiagnosed for many years until overt manifestations of chronic liver disease emerge and liver injury has already reached catastrophic proportions.

Adult patients suffering from unexplained liver disease represent an understudied and underserved population, and, furthermore, the use of whole-exome sequencing (WES) to diagnose the disease remains poorly studied.

To correct this deficiency, investigators at Yale School of Medicine (New Haven, CT, USA) performed WES and deep phenotyping of 19 unrelated adult patients with idiopathic liver disease following an ambiguous conventional work-up performed by a hepatologist. WES is a technique for sequencing all the approximately 20,000 human protein-coding genes. It is suitable for both clinical use and translational research studies.

The investigators reported that in five cases, genomic analysis led to diagnosis and informed treatment and management of the disease. For example, in one case, molecular diagnosis enabled initiation of leptin replacement therapy that restored liver function and decreased daily insulin requirements. In two of the cases, a mitochondrial disorder due to a homozygous pathogenic variant enabled initiation of disease preventive measures including supplementation with antioxidants.

"This study provides evidence that a subset of adult patients who suffer from liver disease of indeterminate etiology with or without other comorbidities harbor an underlying Mendelian disorder, which may be unrecognized during their entire childhood until genetic testing is performed," said senior author Dr. Silvia Vilarinho, assistant professor of medicine and pathology at Yale School of Medicine. "Our data highlight the importance of using WES in the investigation of liver disease of unknown cause so that we may start developing an understanding of what clinical presentations or diseases are genetic and may remain undiagnosed until adulthood."

"Advances in human genomics through next generation sequencing technology have created an unprecedented opportunity for genetic investigation and clinical diagnosis," said Dr. Vilarinho. "However, to date, most studies that investigate the use of next generation sequencing technologies in diagnosis and personalized medical care have been performed in either pediatric or cancer patients. The clinical utility of these approaches for a broader spectrum of diseases among adults remains poorly studied."

The WES study was described in the April 1, 2019, online edition of the Journal of Hepatology.

Related Links:
Yale School of Medicine

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.